Amadix is a biotechnology company focused on the development and commercialization of diagnostic tools for personalized oncology treatment.
Amadix has raised $15.5M in total funding. The most recent round was Debt Financing. The last funding was announced in February 2025.
Amadix's investors include European Investment Bank, Inveready, European Innovation Council, Clave Capital, EISMEA.
Amadix is headquartered in Madrid, Spain.
Amadix is a biotechnology company focused on the development and commercialization of diagnostic tools for personalized oncology treatment.
Amadix is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Amadix — Funding & Investors." VCBacked, February 10, 2025, https://www.vcbacked.co/company/amadix. Accessed September 29, 2026.
VCBacked. (2025). Amadix — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/amadix
{{cite web |title=Amadix — Funding & Investors |url=https://www.vcbacked.co/company/amadix |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated